Full Press Release Details
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s Well Summit , taking place from September 28 to 30, 2026, in New York.
Mr. Fried is scheduled to participate in the Aging on Trial: Peptides, Hormones, and the Line Between Breakthrough and Hype Panel on Tuesday, September 29, from 11:15 a.m. to 12:00 p.m. ET at The Plaza in New York.
Canaccord Genuity’s Well Summit returns for its second year, offering top executives, investors, and innovators shaping the Consumer Health & Wellness sector a unique opportunity to connect and engage.
A replay of the panel webcast will be available on the Niagen Bioscience Investor Relations website, www.investors.niagenbioscience.com , following the event.
For additional information on Niagen Bioscience, visit www.niagenbioscience.com .
About Niagen Bioscience
Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.
At the heart of its clinically tested product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen ® , the number one NAD+ boosting oral supplement in the United States † (available at www.truniagen.com ), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.
Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com , where copies of press releases, news, and financial information are regularly published.
† Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)
Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310.405.5227 kendall.knysch@niagenbio.com Niagen Bioscience Investor Relations Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 Niagen@kcsa.com